Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma
3/5/2014 9:34:56 AM
Copenhagen, Denmark; March 5, 2014 – Genmab A/S (OMX: GEN) announced today that its partner, Janssen Biotech, Inc. (“Janssen”) will start a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The study will compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.
Help employers find you! Check out all the jobs and post your resume.
comments powered by